J Gavila
Overview
Explore the profile of J Gavila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
93
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de la Haba-Rodriguez J, Minguez P, Rojo F, Martin M, Alba E, Servitja S, et al.
J Mammary Gland Biol Neoplasia
. 2024 Nov;
29(1):18.
PMID: 39514034
Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse...
2.
Andreu Y, Soto-Rubio A, Ramos-Campos M, Escriche-Saura A, Martinez M, Gavila J
Sci Rep
. 2022 Nov;
12(1):18673.
PMID: 36333362
To explore the modulatory role of Adjuvant Hormone Therapy (AHT) on health-related quality of life (QoL), subjective well-being and distress prevalence in Breast Cancer (BC) survivors, considering the survival phase....
3.
Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, et al.
Ann Oncol
. 2021 Aug;
32(10):1256-1266.
PMID: 34384882
Background: Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET)....
4.
Ciruelos E, Jerusalem G, Martin M, Tjan-Heijnen V, Neven P, Gavila J, et al.
Clin Transl Oncol
. 2020 Mar;
22(10):1857-1866.
PMID: 32170637
Background: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer. However, the safety profile of this schedule still...
5.
Torregrosa M, Escudero M, Paredero I, Carrasco E, Bermejo B, Gavila J, et al.
Clin Transl Oncol
. 2019 Aug;
21(12):1746-1753.
PMID: 31385227
Introduction: An increase in the number of cancer cases is expected in the near future. Breast cancer (BC) mortality rates increase with age even when adjusted for other variables. Here...
6.
Virizuela J, Garcia A, de Las Penas R, Santaballa A, Andres R, Beato C, et al.
Clin Transl Oncol
. 2019 Jul;
21(12):1788-1789.
PMID: 31346971
No abstract available.
7.
Gavila J, de la Haba J, Bermejo B, Rodriguez-Lescure A, Anton A, Ciruelos E, et al.
Clin Transl Oncol
. 2019 Jun;
22(3):420-428.
PMID: 31203575
Purpose: To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. Materials And Methods:...
8.
Virizuela J, Garcia A, de Las Penas R, Santaballa A, Andres R, Beato C, et al.
Clin Transl Oncol
. 2019 Jan;
21(1):94-105.
PMID: 30627982
One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of...
9.
Ciruelos E, Vidal M, Martinez de Duenas E, Martinez-Janez N, Fernandez Y, Garcia-Saenz J, et al.
Clin Transl Oncol
. 2017 Nov;
20(6):753-760.
PMID: 29116433
Background: Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer. It is necessary, therefore, to characterize the safety profile of this new...
10.
Gavila J, Segui M, Calvo L, Lopez T, Alonso J, Farto M, et al.
Clin Transl Oncol
. 2016 Apr;
19(1):91-104.
PMID: 27101413
Purpose: While much progress has been made in the treatment of breast cancer, cardiac complications resulting from therapy remain a significant concern. Both anthracyclines and novel targeted agents can inflict...